This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for GSSC
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
by Zacks Equity Research
Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSSC
Zacks.com featured highlights include OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham
by Zacks Equity Research
OppFi, Corcept Therapeutics, DXP Enterprises, Perpetua Resources and Graham are part of the Zacks Screen of the Week article.
All You Need to Know About Corcept (CORT) Rating Upgrade to Strong Buy
by Zacks Equity Research
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Buy These 5 Stocks With Recent Price Strength Amid a Volatile January
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are OPFI, CORT, DXPE, PPTA, GHM.
Is Corcept (CORT) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Corcept (CORT) possesses solid growth attributes, which could help it handily outperform the market.
Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept Submits Application for Another Cushing's Syndrome Drug
by Zacks Equity Research
CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
by Zacks Equity Research
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Ionis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPSE
Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.